Model enhanced reinforcement learning to enable precision dosing: A theoretical case study with dosing of propofol.


Journal

CPT: pharmacometrics & systems pharmacology
ISSN: 2163-8306
Titre abrégé: CPT Pharmacometrics Syst Pharmacol
Pays: United States
ID NLM: 101580011

Informations de publication

Date de publication:
11 2022
Historique:
received: 12 07 2022
accepted: 09 08 2022
pubmed: 1 10 2022
medline: 18 11 2022
entrez: 30 9 2022
Statut: ppublish

Résumé

Extending the potential of precision dosing requires evaluating methodologies offering more flexibility and higher degree of personalization. Reinforcement learning (RL) holds promise in its ability to integrate multidimensional data in an adaptive process built toward efficient decision making centered on sustainable value creation. For general anesthesia in intensive care units, RL is applied and automatically adjusts dosing through monitoring of patient's consciousness. We further explore the problem of optimal control of anesthesia with propofol by combining RL with state-of-the-art tools used to inform dosing in drug development. In particular, we used pharmacokinetic-pharmacodynamic (PK-PD) modeling as a simulation engine to generate experience from dosing scenarios, which cannot be tested experimentally. Through simulations, we show that, when learning from retrospective trial data, more than 100 patients are needed to reach an accuracy within the range of what is achieved with a standard dosing solution. However, embedding a model of drug effect within the RL algorithm improves accuracy by reducing errors to target by 90% through learning to take dosing actions maximizing long-term benefit. Data residual variability impacts accuracy while the algorithm efficiently coped with up to 50% interindividual variability in the PK and 25% in the PD model's parameters. We illustrate how extending the state definition of the RL agent with meaningful variables is key to achieve high accuracy of optimal dosing policy. These results suggest that RL constitutes an attractive approach for precision dosing when rich data are available or when complemented with synthetic data from model-based tools used in model-informed drug development.

Identifiants

pubmed: 36177959
doi: 10.1002/psp4.12858
pmc: PMC9662205
doi:

Substances chimiques

Propofol YI7VU623SF

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1497-1510

Informations de copyright

© 2022 The Authors. CPT: Pharmacometrics & Systems Pharmacology published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.

Références

Br J Anaesth. 2018 May;120(5):942-959
pubmed: 29661412
NPJ Digit Med. 2020 Jul 23;3:97
pubmed: 32715091
CPT Pharmacometrics Syst Pharmacol. 2022 Nov;11(11):1497-1510
pubmed: 36177959
Clin Pharmacol Ther. 2020 Apr;107(4):853-857
pubmed: 31955414
Br J Anaesth. 2019 Oct;123(4):430-438
pubmed: 31255290
CPT Pharmacometrics Syst Pharmacol. 2021 Mar;10(3):241-254
pubmed: 33470053
Clin Pharmacol Ther. 2021 Jan;109(1):37-41
pubmed: 33111328
Anesth Analg. 2016 Jan;122(1):56-69
pubmed: 26516804
Br J Anaesth. 1991 Jul;67(1):41-8
pubmed: 1859758
Medicine (Baltimore). 2021 Jan 29;100(4):e23930
pubmed: 33530193
Annu Rev Pharmacol Toxicol. 2018 Jan 6;58:105-122
pubmed: 28961067
Sci Rep. 2021 Sep 9;11(1):17882
pubmed: 34504141
Clin Pharmacokinet. 2018 Nov;57(11):1435-1447
pubmed: 29512049
Clin Transl Sci. 2019 May;12(3):236-239
pubmed: 30791226
Anesth Analg. 2008 Oct;107(4):1200-10
pubmed: 18806028
JAMA. 2021 Apr 20;325(15):1505-1506
pubmed: 33760028
CPT Pharmacometrics Syst Pharmacol. 2022 Jun;11(6):745-754
pubmed: 35582964
Anaesthesia. 2019 Feb;74(2):211-224
pubmed: 30378102
Clin Pharmacol Ther. 2021 Jan;109(1):87-100
pubmed: 32449163
Br J Anaesth. 2022 Jun;128(6):959-970
pubmed: 35361490
Comput Methods Programs Biomed. 2019 May;173:15-26
pubmed: 31046990
Br J Anaesth. 2021 Feb;126(2):386-394
pubmed: 33317804
Am J Health Syst Pharm. 2020 May 19;77(11):835-864
pubmed: 32191793
iScience. 2021 Jun 30;24(7):102804
pubmed: 34308294
Stat Med. 2009 Nov 20;28(26):3294-315
pubmed: 19750510
Anesth Analg. 2017 Feb;124(2):456-464
pubmed: 28099320

Auteurs

Benjamin Ribba (B)

Roche Pharma Research and Early Development (pRED), F. Hoffmann La Roche Ltd., Basel, Switzerland.

Dominic Stefan Bräm (DS)

Roche Pharma Research and Early Development (pRED), F. Hoffmann La Roche Ltd., Basel, Switzerland.

Paul Gabriel Baverel (PG)

Roche Pharma Research and Early Development (pRED), F. Hoffmann La Roche Ltd., Basel, Switzerland.

Richard Wilson Peck (RW)

Roche Pharma Research and Early Development (pRED), F. Hoffmann La Roche Ltd., Basel, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH